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Abstract
Type II DNA topoisomerases are ubiquitous enzymes with essential functions in DNA replication, recombination and
transcription. They change DNA topology by forming a transient covalent cleavage complex with a gate-DNA duplex that
allows transport of a second duplex though the gate. Despite its biological importance and targeting by anticancer and
antibacterial drugs, cleavage complex formation and reversal is not understood for any type II enzyme. To address the
mechanism, we have used X-ray crystallography to study sequential states in the formation and reversal of a DNA cleavage
complex by topoisomerase IV from Streptococcus pneumoniae, the bacterial type II enzyme involved in chromosome
segregation. A high resolution structure of the complex captured by a novel antibacterial dione reveals two drug molecules
intercalated at a cleaved B-form DNA gate and anchored by drug-specific protein contacts. Dione release generated drug-
free cleaved and resealed DNA complexes in which the DNA gate instead adopts an unusual A/B-form helical conformation
with a Mg2+ ion repositioned to coordinate each scissile phosphodiester group and promote reversible cleavage by active-
site tyrosines. These structures, the first for putative reaction intermediates of a type II topoisomerase, suggest how a type II
enzyme reseals DNA during its normal reaction cycle and illuminate aspects of drug arrest important for the development of
new topoisomerase-targeting therapeutics.
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Introduction
The bacterial type II enzymes topoisomerase IV and gyrase
have important roles in DNA replication [1–4]. Topoisomerase
IV, a tetramer of two ParC and two ParE subunits, unlinks
daughter chromosomes prior to cell division whereas the related
enzyme gyrase, a GyrA2GyrB2 tetramer, supercoils DNA and
helps unwind DNA at replication forks [3]. Both enzymes act via
a double-strand DNA break involving a cleavage complex
(Figure S1 and Movie S1). Detailed understanding of their
reaction pathway has been frustrated by the transient nature of
this key intermediate and the absence of relevant drug-free
structures. Antibacterial fluoroquinolones stabilize the cleavage
complex in a Mg2+-dependent fashion facilitating biochemical
and structural work [3,5]. Recent studies have also identified
quinazolinediones as a new class of topoisomerase IV inhibitors
with activity against Streptococcus pneumoniae and other Gram-
positive pathogens [6–8]. Here we use a novel quinazolinedione
to generate crystals of Streptococcus pneumoniae topoisomerase IV
captured as a cleavage complex, and by exploiting the slow
resealing of the complex [9], we have now obtained the first
diffracting crystals of sequential catalytically-competent drug-
free-DNA cleaved and resealed complexes. The structures of
these complexes explain unique dione activities (such as lack
of cross-resistance with quinolones [9–11]) and provide a
structural basis for reversible DNA strand breakage by a type
II topoisomerase.
Results and Discussion
We co-crystallized the potent dione PD 0305970 with the S.
pneumoniae ParC breakage-reunion domain (ParC55, residues 1–
488) and ParE TOPRIM domain (ParE30, residues 404–647) in
the presence of a 34-bp DNA duplex (the E-site) [12] (Figures 1
and 2). The X-ray crystal structure of the complex was determined
to 3.1 A˚ revealing a closed ParC55 dimer flanked by two ParE30
monomers (Figure 1). In contrast to a yeast topoisomerase II core
domain in complex with an artificially-nicked surrogate DNA
substrate [13], the C-terminal C-gate region (comprising helices
a14, a18 and a19) is closed in the dione structure as it is in lower
resolution quinolone structures [5]. The G-segment DNA is bound
across the ParC dimer interface in a ‘U shape’ in which the central
18-bp region is well resolved. This region carries a 4-bp staggered
DNA break in which the two active site ParC Tyr 118 residues are
linked covalently to the 59 phosphate ends of the break. Two dione
molecules are intercalated in the space between the +1 and –1
nucleotides at the two ends of the staggered DNA cut. These
features confirm the capture of a dione-stabilized complex, the first
high resolution structure of a cleavage complex reported for a type
II topoisomerase.
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The structure reveals the disposition of protein side-chains,
magnesium ions and DNA that form the drug binding pockets
(Figure 2A and Figure S2A). The dione sits on the purine base at
+1 with the electronegative fluorine at C-6 (optimal for drug
activity) interacting with partially charged atoms in the DNA bases
(Figure S2A). We interpret additional density close to the non-
scissile phosphodiester linking 21 and 22 nucleotides as a Mg2+
ion, consistent with its complexation by Asp 506 and Asp 508, two
conserved metal binding residues of the TOPRIM domain [4].
The dione C-2 oxygen makes a key hydrogen-bonded contact with
the side-chain of Arg 117, a conserved active-site residue from
ParC. The Ser 79 and Asp 83 residues of ParC that are mutated in
quinolone resistance [10,11] are well removed from the dione N-3
amino group, whereas the conserved ParE Arg 456, Glu 474, Glu
475 and Asp 435 residues altered in dione resistance [9] are
clustered around the dione C-7 group. Overall, the structure
plausibly accounts for the known antimicrobial properties of the
diones [9].
Release of dione could be demonstrated by sequential
desoaking/soaking with fluoroquinolones affording the levoflox-
acin cleavage complex with topo IV which we solved at 2.9 A˚. The
overall architecture of the dione and levofloxacin complexes
appears similar, but in fact the drugs are bound differently
(Figure 2 and Figure S2). Thus, the ParC residues Ser 79 (mutated
in quinolone resistance) and Arg 117 are both coordinated to the
levofloxacin C-3 carboxyl through a highly mobile hydrogen-
bonded water molecule (absent in the dione structure). Disruption
of these contacts in Ser 79 mutants may destabilise drug binding
leading to quinolone resistance. Conversely, the bound quinolone
does not interact with ParE Glu 474 and Glu 475 residues mutated
in dione resistance (Figure S2). The engagement of different
protein side-chains accounts for the differential activities and lack
of cross-resistance between the dione and quinolone classes of
antimicrobial agents [9].
Slow resealing of dione cleavage complexes [9] led us to prepare
crystals of the dione complex that had been soaked sequentially
with EDTA and then with MgCl2. The respective structures solved
at 3.3 A˚ and 3.5 A˚ revealed that in each case the dione had been
released, but remarkably the DNA remained cleaved after EDTA
and had become resealed following further incubation in the
presence of Mg2+. These structures represent potential cleavage
(Figure 3B) and pre-cleavage (Figure 3C) reaction intermediates
and thus provide new insight on events at the gate-DNA notably
the role of Mg2+ (Figure 3) and DNA conformation (Figure 4).
Consistent with this idea, in the sealed DNA complex (Figure 3C),
the OH group of Tyr 118 is poised to undergo nucleophilic attack
on the phosphorus atom of the phosphodiester group linking +1
and –1 nucleotides potentiated by the positively-charged side-
chain of the highly conserved Arg 117. Furthermore, a Mg2+ ion
now coordinated by Glu 433 and Asp 506 is bound to bridging
and apical oxygens of the scissile phosphodiester moiety facilitating
tyrosyl attack by stabilizing both the incipient 39-OH leaving
group and tyrosyl phosphate group, as seen in the cleaved complex
(Figure 3B). Thus, the Mg2+ ions have been repositioned to occupy
new sites at which they can promote catalysis at scissile
phosphates, a major difference with drug-bound structures
(Figure 3A and Figure S2).
Recent biochemical studies have led to a two-metal ion model
for DNA cleavage by gyrase and topoisomerase II, as seen for
some other (though not all) phosphodiester processing enzymes
[4,14–16]. One Mg2+ is suggested to bind the 39 bridging oxygen
of the scissile phosphodiester bond stabilizing the 39 OH leaving
group, with a second ion potentiating the catalytic tyrosine OH
[4,15,16]. Interestingly, in our structures of catalytically competent
cleaved and resealed DNA states, a single ion at each scissile DNA
site coordinates both sets of reactive DNA groups. Although we
cannot exclude the participation of a second more weakly bound
Mg2+ perhaps stabilised somehow in the holoenzyme, we see no
evidence for it in our crystal structures suggesting the possibility
that, at least for topoisomerase IV, a single ‘dynamic’ Mg2+ is
sufficient for transphosphorylation. Similar considerations may
hold for the TOPRIM domain of type I topoisomerases that act
through a single-strand DNA break [4].
Access to dione-stabilized and drug-free enzyme complexes
greatly enhances our understanding of the G-gate and its arrest by
drugs (Figure S2, Figure 3 and Figure 4). Drug intercalation
critically affects the disposition of catalytic groups within the
complex, tying up the active site Arg 117, pushing the reactive 39
Figure 1. Architecture of a dione-arrested DNA complex of topoisomerase IV. A–B, Orthogonal views of the topo IV-DNA complex
stabilized by PD 0305970. ParC is in purple/yellow, ParE is in salad green/light rose, DNA strands are in pink, blue, orange and light-green, PD 0305970
is in dark blue.
doi:10.1371/journal.pone.0011338.g001
S. pneumoniae Topo IV Gate
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OH and 59 phosphate DNA ends far apart (5.9 A˚) and displacing
Mg2+ ions by 4 A˚ (Figure 3A and Figure S2A). Moreover, DNA
analysis using the program 3DNA [17,18] reveals major
differences in DNA conformation at the gate (Figure 4). Thus,
the drug-free and drug-stabilised complexes all bind the G-DNA
in a U-shaped fashion facilitated by the symmetrical DNA
insertion of the side-chains of ParC Ile 170 residues between
nucleotides +8 and +9 on each strand and flanking the DNA
cleavage sites (Figure 4A). The middle 8 nucleotides (22 to +6)
encompassing the cleavage sites adopt the A-helix conformation in
the drug-free complexes (Figure 4C, D) but B-form DNA in the
drug-stabilised complexes (Figure 4B), whereas the outer regions of
the G-DNA are B-form in all cases (Figure 4B–D). The backbone
of the G-DNA is trapped within the DNA-binding groove of the
protein by both van der Waals and electrostatic interaction (Figure
S3A). Basic residues together with the active site magnesium ion
run along the DNA backbone, while the neutral side-chain of
ParC Ile 170 intercalates into the minor groove. The DNA
conformation is further stabilised by the a4 helix intercalated into
the major groove. The G-segment is forced into the stretched and
unwound A-form conformation (Figure 3B,C) suggesting that A-
form DNA may be required for proper gate alignment, cleavage
and separation prior to DNA transport. The role of Mg2+ would
be to oppose separation and promote DNA religation by
coordinating the 59 and 39 ends of the G-segment. By displacing
Mg2+ closer to the 21 backbone phosphate group, dione binding
promotes cleavage and may favour ‘relaxation’ of the G-DNA into
the B-form conformation. These results provide the first three-
dimensional insights on events at the G gate.
Reversible cleavage at a gate-DNA is the salient feature
underlying the biological activities of all type II topoisomerases
yet the nature of this process has hitherto remained obscure. Our
structural analysis of dione- and quinolone-stabilized complexes of
topoisomerase IV alongside catalytically competent cleaved and
resealed states now provides a detailed picture of the architecture
of the G-DNA gate and of the events that occur during DNA
Figure 2. Unique interactions govern topoisomerase IV arrest on DNA. A and B, Cartoon/stick representation of the drug-binding pockets
of topoisomerase IV-DNA in complex with PD 0305970 and levofloxacin, respectively. The sA-weighted 2Fobs-Fcalc map is contoured around PD
0305970 (pink) and levofloxacin (light-blue) at 1.5s. C, Domain organization of topo IV from S. pneumoniae with individual sub-regions highlighted
by individual colours. Resistance mutation sites within the topoisomerase sequence are indicated by red lines.
doi:10.1371/journal.pone.0011338.g002
S. pneumoniae Topo IV Gate
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breakage and reversal. The work sheds new light on the
mechanistic roles of Mg2+ and DNA conformation at the G-gate,
and elucidates how different classes of antibacterial agents interfere
with DNA resealing. These insights should aid the design of new
antimicrobial agents able to circumvent resistance through novel
interactions at the topoisomerase-DNA interface.
Materials and Methods
Proteins and DNA
S. pneumoniae ParC55 (residues 1–488) and ParE30 (residues
404–647) were produced as the C-terminally and N-terminally
His-tagged proteins by over-expression in E. coli and purified as
Figure 3. Topoisomerase IV active site with cleaved and resealed DNA. A–C, Repositioning of Mg2+, DNA and active-site amino acids (Arg
117 and Tyr 118 from ParC; Glu 433, Asp 506 and Asp 508 from ParE) in sequential drug-stabilized (A), drug-free cleaved (B) and drug-free re-sealed
(C) topo IV-DNA cleavage complexes, respectively. Current and previous positions of the magnesium ion are shown in light-purple and grey
correspondingly. Close intermolecular contacts are indicated by dotted lines.
doi:10.1371/journal.pone.0011338.g003
Figure 4. Molecular and conformational changes at the DNA gate. A, E-site DNA sequence with important positions involved in protein-DNA
and PD 0305970-DNA interactions indicated. The highlighted 18-bp region is well resolved in the crystal structures. B–D, Drug-stabilised, drug-free
cleaved and drug-free re-sealed topo IV-DNA cleavage complexes respectively. The DNA is in blue/yellow for backbone/bases. Active site tyrosines
are in orange, intercalating isoleucines are in red and magnesium ions are in purple. The sA-weighted 2Fobs-Fcalc map is contoured around the DNA/
Tyr 118 of the structure at 1.5s (light-blue). In B the PD 0305970 molecules are in green. The remaining parts of the complex are omitted for clarity.
doi:10.1371/journal.pone.0011338.g004
S. pneumoniae Topo IV Gate
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described previously [5,19]. DNA oligomers (59-ACCAAGGT-
CATGAATGACTATGCACGTAAAACAG-39, 59-CTGTTT-
TACGTGCATAGTCATTCATGACCTTGGT-39) were both
synthesized by solid-phase phosphoramidite chemistry and doubly
HPLC purified by Metabion, Munich.
Crystallization
Equimolar amounts of ParC55 and ParE30 were incubated (at 4
mg/ml) with the 34 base-pair DNA binding site fragment (1:1:1.2
molar ratio respectively) and quinazolinedione PD 0305970
(30 mg/ml) in buffer A (20 mM Tris-HCl pH 7.0, 200 mM NaCl,
10% glycerol (v/v), 1 mM b-mercaptoethanol, 20 mM MgCl2,
0.05% NaN3 (w/v)) at room temperature for two days. The
mixture then was dialysed overnight against the buffer B (20 mM
Tris-HCl pH 7.0, 75 mM NaCl, 10% glycerol (v/v), 1 mM b-
mercaptoethanol, 20 mM MgCl2, 0.05% NaN3 (w/v), 1 mg/ml
PD 0305970). Then, PD 0305970 was added to a final
concentration of 31 mg/ml and the mixture was further incubated
at room temperature overnight. Crystallization was performed
both by conventional hanging drop vapour diffusion in 24-well
Limbro plates (4+2 ml protein mix/reservoir) and by sitting drop in
96-well MRC crystallization plates (600+300 nl protein mix/
reservoir). Crystals formed after 7 days from 50 mM Na
cacodylate, pH 6.5, 2.5% TacsimateTM, pH 7.0 (Hampton
Research Corp.) [20], 62.5 mM KCl, 7.5 mM MgCl2, 4–6% (v/
v) isopropanol and continued to grow for another 7 days. The
crystals were flash-cooled to 100 K into a cryoprotectant buffer C
(50 mM Na cacodylate, pH 6.5, 2.5% TacsimateTM, pH 7.0
(Hampton Research Corp.) [20], 62.5 mM KCl, 7.5 mM MgCl2,
1 mM b-mercaptoethanol, 30% (v/v) MPD). The best crystals
were used to collect the native PD 0305970 datasets with the best
resolution of 3.1 A˚ obtained at the Diamond synchrotron light
source, UK. The remaining crystals were harvested into the
cryoprotectant buffer C and subjected to 6 changes of the solution
(at least 1:100 dilution each time) with 1-hour intervals in order to
back-soak out PD 0305970 from the crystal lattice/remove it from
the solution. Subsequently, crystals were divided into groups and
each group was soaked overnight in 300 ml cryoprotectant buffer
C containing in addition one of the following: 10 mM EDTA
(referred to as EDTA crystals) or 3 mM levofloxacin. The best
crystals from these groups were flash-cooled in the nitrogen
cryostream (100 K). A few crystals from the EDTA-soaked group
were subjected to 6 changes of cryoprotectant buffer C over a
period of 8 hours in order to remove EDTA and re-introduce
Mg2+ ions (later on referred to as EDTA-Mg crystals). The best
crystals from this group were also flash-cooled in the nitrogen
cryostream and used for data collection at the Diamond
synchrotron.
Data Collection
Crystals were tested in-house for diffraction quality using an
Oxford Xcalibur Nova CCD diffractometer and then transported
for high-resolution data collection at the Diamond Light Source
(Oxford, UK) (beamline I03, wavelength 0.97630 A˚) using ADSC
quantum 315 detectors. Data were integrated and reduced using
HKL2000 [21]. To our surprise, the levofloxacin-soaked crystals
exhibited good quality diffraction and a relatively high intensity of
diffracted reflections to high angle, exceeding that for one of the
best native PD 0305970-containing crystals and all other soaked
crystals. The diffraction reached a resolution of 2.9 A˚ with some
anisotropic data extending up to 2.6 A˚. The best dataset obtained
so far for the native PD 0305970-containing crystal extends up to
3.1 A˚. Crystals soaked using other drugs as well as the crystals
from which PD 0305970 was back-soaked out, diffracted to a
lower resolution and did not show a clear and interpretable drug
envelope in the 2Fobs-Fcalc maps after refinement. By contrast,
EDTA and EDTA-Mg crystals exhibited diffraction patterns of
relatively high intensity and the resolution of the data obtained
extended up to 3.3 A˚ and 3.5 A˚ respectively. The highest
resolution dataset (from a levofloxacin-soaked crystal) was used
to obtain the structure solution and refinement. The structure was
solved by molecular replacement in Phaser [22] using as search
models our cleavage complex of topo IV from S. pneumoniae with
moxifloxacin [5]. Refinement was performed in Phenix [23] using
the secondary structure restraints derived from the previously
solved complex. Rigid body, simulated annealing, positional and
TLS refinement has been performed. The refined model with the
drug molecules omitted was used to solve the structures of the
native PD 0305970-containing crystals as well as the EDTA and
EDTA-Mg crystals. For all these additional structures, rigid body
refinement, simulated annealing, positional and TLS refinement
were performed. The drug molecules, magnesium ions and water
molecules were placed during the last stages of refinement
according to the missing electron density in the sA-weighted
2Fobs-Fcalc and Fobs-Fcalc maps. WinCoot [24] was used for
interactive model fitting. The structures were verified using
WinCoot and ProCheck [25,26]. The models had good geometry
with 82.5/16.2/1.0 (PD 0305970-stabilised cleavage complex),
86.8/11.8/1.1 (levofloxacin-stabilised cleavage complex), 83.9/
13.8/1.6 (drug-free complex with cleaved DNA) and 82.4/15.4/
1.4 (drug-free complex with re-sealed DNA) percent of residues in
favoured/allowed/generously allowed regions of the Ramachan-
dran plot, respectively, and no more than 0.3–0.7% of residues in
disallowed regions. The final data collection refinement statistics
are given in Table S1. DNA conformation (A/B-form) was
analysed using 3DNA [17,18]. Figures were prepared using
PyMOL [27].
To our surprise, the EDTA-soaked crystals did not lose Mg2+
ion as it could still be found in the electron density coordinating
several negatively charged residues such as Glu 433, Asp 506 as
well as the 59 phosphate groups. The drug had been completely
removed, however, the DNA was still cleaved and covalently
attached to the active site tyrosines (i.e., drug-free cleaved
complex). A similar situation was observed for the EDTA-Mg
crystals although in this case the DNA was re-sealed (i.e., drug-free
resealed complex). Since apparently the Mg2+ ions were retained
throughout the process of drug removal and DNA resealing, the
role of EDTA in this process remains unclear and the most
plausible explanation is that the in-crystal DNA resealing required
a longer time than removing the drug by back-soaking. Slow
resealing in solution of topoisomerase IV-dione-DNA cleavage
complexes following EDTA addition has been reported previously
[9], and was at least 60-fold slower than that seen with levofloxacin
(X.-S. Pan and L.M. Fisher, unpublished results).
Atomic coordinates and structure factors have been deposited in
the Protein Data Bank under accession numbers 3LTN (complex
with PD 0305970), 3K9F (complex with levofloxacin), 3KSA (drug-
free cleaved complex) and 3KSB (drug-free resealed complex). Raw
diffraction images are available on request. Correspondence and
request for materials should be addressed to L.M.F and M.R.S
(lfisher@sgul.ac.uk, mark.sanderson@kcl.ac.uk).
‘Note Added In Proof: Our manuscript was submitted on April
29, 2010. Whilst our paper was under review, another study
appeared (Schmidt BH et al. Nature 2010 May 19 [Epub ahead of
print] describing a structure of yeast topo II core domain in
complex with Zn2+ ions and an artificially nicked phosphorothio-
late DNA substrate’. It may be mentioned that the four structures
we present here involve topoisomerase IV with natural DNA
S. pneumoniae Topo IV Gate
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substrate and Mg2+ ions and give information for cleaved and
resealed complexes determined both in the absence and presence
of dione/quinolone drugs’.
Supporting Information
Figure S1 Schematic model of the DNA transport mechanism
employed by a type II DNA topoisomerase and its inhibition by
antibacterial/anticancer drug action. The diagram is built using a
model of the full-length topo IV which, in turn, is based on the
crystal structure of the drug-free cleavage complex of topo IV from
S. pneumoniae with cleaved DNA (reported in this paper, 3KSA,
covering the N-terminal domain of ParC, C-terminal domain of
ParE and bound/cleaved G-segment) as well as the crystal
structures of the C-terminal domain of GyrA from B. burgdorferi
(1SUU)1 (for C-terminal domain of ParC) and the N-terminal
domain of GyrB from E. coli (1EI1) (for N-terminal domain of
ParE)2. Unbound G-segment and the transported T-segment were
generated using WinCoot3. N-terminal domain of ParC is shown
in blue, C-terminal domain of ParC is in cyan, N-terminal domain
of ParE is in purple, C-terminal domain of ParE is in yellow, G-
segment is in green and T-segment is in red. DL stands for a
change in the linking number of the DNA per cycle. An animated
version of this scheme is available as the Supporting Movie S1
online.
Found at: doi:10.1371/journal.pone.0011338.s001 (2.41 MB TIF)
Figure S2 Key interactions within drug-stabilized cleavage
complexes of S. pneumoniae topoisomerase IV. The cleavage
complexes are stabilized by quinazolinedione PD 0305970 (A)
and quinolone levofloxacin (B). The important inter-atomic
distances are shown in A˚ngstroms and indicated by arrows.
Magnesium ion is in purple, tyrosine is in cyan, DNA bases are in
green, DNA sugars are in grey, PD 0305970 is in yellow,
levofloxacin is in ‘rose’ and water molecule is in light pink.
Nitrogen, oxygen and phosphorus atoms are in blue, red and
orange, respectively.
Found at: doi:10.1371/journal.pone.0011338.s002 (1.15 MB TIF)
Figure S3 Specifics of the G-segment binding groove and DNA
curvature (stereograms). A, Key elements of the DNA-binding cleft
of topo IV from S. pneumoniae. Residues within 5 A˚ distance from
the DNA molecule are shown in surface representation. Side-
chains of basic/acidic amino acids are in blue/red respectively.
Active site tyrosine is in orange, the side-chain of intercalating
isoleucine 170 is in green, the magnesium ion is in yellow. The G
DNA fragment is shown in cartoon representation (cyan). The rest
of the complex is omitted for clarity. B and C, modelled ideal A-
form and B-form DNA molecules with curvatures of 27 and 33 A˚
respectively superposed onto the re-sealed G-segment. Models
were prepared using CNS4. The figure panels were rendered in
VMD5.
Found at: doi:10.1371/journal.pone.0011338.s003 (4.38 MB TIF)
Table S1 Data collection and refinement statistics and Support-
ing References.
Found at: doi:10.1371/journal.pone.0011338.s004 (0.06 MB
DOC)
Movie S1 Animated model of the DNA transport mechanism
employed by a type II DNA topoisomerases. The animation is
created using a model of the full-length topo IV which, in turn, is
based on the crystal structure of the drug-free cleavage complex of
topo IV from S. pneumoniae with cleaved DNA (reported in this
paper, 3KSA, covering N-terminal domain of ParC, C-terminal
domain of ParE and bound/cleaved G-segment) as well as the
crystal structures of the C-terminal domain of GyrA from B.
burgdorferi (1SUU)1 (for C terminal domain of ParC) and N-
terminal domain of GyrB from E. coli (for N-terminal domain of
ParE)2. Unbound G-segment and the transported T-segment were
generated using WinCoot3. N-terminal domain of ParC is shown
in blue, C-terminal domain of ParC in cyan, N-terminal domain of
ParE in purple, C-terminal domain of ParE in yellow, G-segment
in green and T-segment in red.
Found at: doi:10.1371/journal.pone.0011338.s005 (8.24 MB
MPG)
Acknowledgments
We thank Pfizer for providing PD 0305970.
Author Contributions
Conceived and designed the experiments: IL XSP LMF MRS. Performed
the experiments: IL XSP DAV KEM MRS. Analyzed the data: IL XSP
DAV KEM LMF MRS. Contributed reagents/materials/analysis tools: IL
XSP LMF MRS. Wrote the paper: IL XSP LMF MRS.
References
1. Schoeffler AJ, Berger JM (2008) DNA topoisomerases: harnessing and
constraining energy to govern chromosome topology. Q Rev Biophys 41:
41–101.
2. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat
Rev Cancer 9: 338–350.
3. Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial
death. Antimicrob Agents Chemother 52: 385–392.
4. Sissi C, Palumbo M (2009) Effects of magnesium and related divalent metal ions
in topoisomerase structure and function. Nucleic Acids Res 37: 702–711.
5. Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, et al. (2009)
Structural insight into the quinolone-DNA cleavage complex of type IIA
topoisomerases. Nat Struct Mol Biol 16: 667–669.
6. Ellsworth EL, Tran TP, Showalter HD, Sanchez JP, Watson BM, et al. (2006) 3-
aminoquinazolinediones as a new class of antibacterial agents demonstrating
excellent antibacterial activity against wild-type and multidrug resistant
organisms. J Med Chem 49: 6435–6438.
7. Tran TP, Ellsworth EL, Sanchez JP, Watson BM, Stier MA, et al. (2007)
Structure-activity relationships of 3-aminoquinazolinediones, a new class of
bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg
Med Chem Lett 17: 1312–1320.
8. Huband MD, Cohen MA, Zurack M, Hanna DL, Skerlos LA, et al. (2007) In
vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial
gyrase/topoisomerase inhibitors with potent antibacterial activities versus
multidrug-resistant gram-positive and fastidious organism groups. Antimicrob
Agents Chemother 51: 1191–1201.
9. Pan XS, Gould KA, Fisher LM (2009) Probing the differential interactions of
quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase
IV. Antimicrob Agents Chemother 53: 3822–3831.
10. Pan XS, Ambler J, Mehtar S, Fisher LM (1996) Involvement of topoisomerase
IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Antimicrob Agents Chemother 40: 2321–2326.
11. Pan XS, Fisher LM (1997) Targeting of DNA gyrase in Streptococcus pneumoniae by
sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Antimicrob Agents Chemother 41: 471–474.
12. Leo E, Gould KA, Pan XS, Capranico G, Sanderson MR, et al. (2005) Novel
symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae
topoisomerase IV and gyrase are clustered at the DNA breakage site. J Biol
Chem 280: 14252–14263.
13. Dong KC, Berger JM (2007) Structural basis for gate-DNA recognition and
bending by type IIA topoisomerases. Nature 450: 1201–1205.
14. West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, et al. (2000)
Mutagenesis of E477 or K505 in the B’ domain of human topoisomerase IIb
increases the requirement for magnesium ions during strand passage.
Biochemistry 39: 1223–1233.
15. Noble CG, Maxwell A (2002) The role of GyrB in the DNA cleavage-religation
reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol 318:
361–371.
16. Deweese JE, Burgin AB, Osheroff N (2008) Human topoisomerase IIa uses
a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res 36: 4883–
4893.
S. pneumoniae Topo IV Gate
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11338
17. Lu XJ, Olson WK (2003) 3DNA: a software package for the analysis, rebuilding
and visualization of three-dimensional nucleic acid structures. Nucleic Acids Res
31: 5108–5121.
18. Lu XJ, Olson WK (2008) 3DNA: a versatile, integrated software system for the
analysis, rebuilding and visualization of three-dimensional nucleic-acid struc-
tures. Nat Protoc 3: 1213–1227.
19. Laponogov I, Veselkov DA, Sohi MK, Pan XS, Achari A, et al. (2007) Breakage-
reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a
gram-positive quinolone target. PLoS One 2: e301.
20. McPherson A, Cudney B (2006) Searching for silver bullets: an alternative
strategy for crystallizing macromolecules. J Struct Biol 156: 387–406.
21. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in
oscillation mode. Method Enzymol. pp 307–325.
22. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al.
(2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
23. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al.
(2002) PHENIX: building new software for automated crystallographic structure
determination. Acta Crystallogr D Biol Crystallogr 58: 1948–1954.
24. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
25. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM (1992) Stereo-
chemical quality of protein structure coordinates. Proteins 12: 345–364.
26. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK:
a program to check the stereochemical quality of protein structures. J Appl
Crystallogr 26: 283–291.
27. DeLano WL (2008) The PyMOL molecular graphics system. DeLano Scientific
LLC, Palo Alto, CA, USA, http://www.pymol.org.
S. pneumoniae Topo IV Gate
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11338
